InspireMD, Inc.
Close on Oct 19, 2026
- Market cap
- $37.25M
- P/E (TTM)
- –
- Dividend yield
- –
Earnings
Next report expected Nov 3, 2026, during market hours (estimated from past report dates)
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q2 FY2026 Ended Jun 30, 2026 | Aug 17, 2026 | Before market open | $1.77M | $-0.17 | – |
| Q1 FY2026 Ended Mar 31, 2026 | May 4, 2026 | During market hours | $3.40M | $-0.16 | – |
| Q4 FY2025 Ended Dec 31, 2025 | Mar 18, 2026 | Before market open | $3.10M | $-0.14 | – |
| Q3 FY2025 Ended Sep 30, 2025 | Nov 4, 2025 | During market hours | $2.50M | $-0.17 | – |
| Q2 FY2025 Ended Jun 30, 2025 | Aug 5, 2025 | Before market open | – | $-0.26 | – |
| Q1 FY2025 Ended Mar 31, 2025 | May 9, 2025 | Before market open | $1.53M | $-0.22 | – |
| Q4 FY2024 Ended Dec 31, 2024 | Mar 12, 2025 | Before market open | $1.95M | $-0.19 | – |
| Q2 FY2024 Ended Jun 30, 2024 | Aug 6, 2024 | Before market open | $1.74M | $-0.22 | – |
| Q1 FY2024 Ended Mar 31, 2024 | May 14, 2024 | Before market open | – | – | – |
| Q4 FY2023 Ended Dec 31, 2023 | Mar 6, 2024 | Before market open | – | – | – |
| Q3 FY2023 Ended Sep 30, 2023 | Nov 6, 2023 | Before market open | – | – | – |
Company guidance
Outlook given with results on Mar 18, 2026, compared with the previous outlook
| Measure | Period | Guidance | vs. prior |
|---|---|---|---|
| expected revenue growth | full year 2026 | 45% to 65% growth | New |
| revenue | full year 2026 | $13.00M to $15.00M | New |
Figures and the sentence they come from are taken from the company's earnings release. Hover a measure to read the source sentence.
Press releases
Announcements InspireMD filed with the SEC
Announces Amendments to Certain Series J and Series K Warrants, Providing Potential Gross Proceeds of Up to $11 Million
Material agreement · Unregistered share sale · Regulation FD disclosure · EX-99.1 to Form 8-K
Reports Second Quarter 2026 Financial Results
Results of operations · EX-99.1 to Form 8-K
Announces 30-Day Results from the CGUARDIANS II Clinical Trial of the CGuard Prime 80 cm Implant for Use in TCAR Procedures
Regulation FD disclosure · EX-99.1 to Form 8-K
Reports First Quarter 2026 Financial Results
Results of operations · EX-99.1 to Form 8-K
Initiates Voluntary U.S. Recall of CGuard ® Prime 135 cm
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
of Investigational Device Exemption for CGUARDIANS III Pivotal Study of the SwitchGuard Neuro Protection System
Regulation FD disclosure · Other events · EX-99.2 to Form 8-K
Reports Fourth Quarter and Full Year 2025 Financial Results
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
EX-99.2 to Form 8-K
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
Reports Third Quarter 2025 Financial Results
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
EX-99.2 to Form 8-K
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
Announces the Appointment of Dan Dearen to its Board of Directors
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
Reports Second Quarter 2025 Financial Results
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
EX-99.2 to Form 8-K
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
Announces Combined Financings of $58 Million
Material agreement · Unregistered share sale · Executive or director change · Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Announces the Appointment of Raymond W. Cohen to its Board of Directors
Material agreement · Unregistered share sale · Executive or director change · Regulation FD disclosure · Other events · EX-99.2 to Form 8-K
Announces U.S. Commercial Launch of CGuard ® Prime Carotid Stent System for the Prevention of Stroke
Regulation FD disclosure · EX-99.1 to Form 8-K
Announces FDA Approval for CGuard ® Prime Carotid Stent System for the
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
EX-99.2 to Form 8-K
Regulation FD disclosure · Other events · EX-99.2 to Form 8-K
InspireMD Announces CE Mark Approval for CGuard ®
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Announces Appointment of Michael Lawless as Chief Financial Officer
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
EMPLOYMENT AGREEMENT (this “ Agreement ”) is dated as of June 2, 2025, and is entered into by and between
Executive or director change · Regulation FD disclosure · EX-99.2 to Form 8-K
Reports First Quarter 2025 Financial Results
Results of operations · EX-99.1 to Form 8-K
Reports Fourth Quarter and Full Year 2024 Financial Results
Results of operations · EX-99.1 to Form 8-K
Announces Expected Retirement of its CFO Craig Shore
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
Announces First Patient Enrolled in the CGUARDIANS II Pivotal Study of the CGuard Prime Carotid Stent System in Transcarotid Artery Revascularization
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Announces Appointment of Accomplished Medical Technology Executive
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
Reports Third Quarter 2024 Financial Results and Provides
Regulation FD disclosure · EX-99.1 to Form 8-K
Announces Establishment of Global Headquarters in Miami, Florida to Support Anticipated U.S. Launch and Commercialization of the CGuard
Material agreement · Regulation FD disclosure · EX-99.1 to Form 8-K
Announces Approval of Investigational Device Exemption (IDE) Application for CGUARDIANS II Pivotal Study of the CGuard Prime 80cm Carotid
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Announces Submission of Premarket Approval Application to FDA Seeking U.S. Regulatory Approval of the CGuard™ Prime Carotid Stent
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Reports Second Quarter 2024 Financial Results and Provides
Results of operations · EX-99.1 to Form 8-K
Announces Full Exercise of Series H Warrant Tranche for
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
EX-99.1 to Form 8-K
Regulation FD disclosure · EX-99.1 to Form 8-K
Announces Presentation of Positive One-Year Follow-Up Results from the
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
EX-99.2 to Form 8-K
Regulation FD disclosure · Other events · EX-99.2 to Form 8-K
Reports First Quarter 2024 Financial Results and Provides
Results of operations · EX-99.1 to Form 8-K
Announces Abstract of One-Year Follow-Up Results from the
Regulation FD disclosure · EX-99.1 to Form 8-K
Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Business Update
Results of operations · EX-99.1 to Form 8-K
Receives CE Mark Recertification Under EU’s New Medical Device Regulation (MDR) Regulatory Framework
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Announces Issuance of Key U.S. Patent Covering Its SwitchGuard TM Neuroprotection System
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K